Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factorsKOCH, K. M; CORRIGAN, B. W; MANZO, J et al.Alimentary pharmacology & therapeutics. 2004, Vol 20, Num 2, pp 223-230, issn 0269-2813, 8 p.Article

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndromeDELVAUX, M; LOUVEL, D; MAMET, J.-P et al.Alimentary pharmacology & therapeutics. 1998, Vol 12, Num 9, pp 849-855, issn 0269-2813Article

Serotonergic modulation of visceral sensation: lower gutCAMILLERI, M.Gut. 2002, Vol 51, pp 81-86, issn 0017-5749, SUP1Conference Paper

Effectiveness of Probiotics in the Treatment of Irritable Bowel SyndromeWILHELM, Sheila M; BRUBAKER, Christine M; VARCAK, Elizabeth A et al.Pharmacotherapy. 2008, Vol 28, Num 4, pp 496-505, issn 0277-0008, 10 p.Article

Acute hepatitis associated with alosetron (Lotronex®)TURGEON, D. Kim; TAYEH, Nadia; FONTANA, Robert J et al.Journal of clinical gastroenterology. 2005, Vol 39, Num 7, pp 641-642, issn 0192-0790, 2 p.Article

Alosetron: a case study in regulatory capture, or a victory for patients' rights?MOYNIHAN, Ray.BMJ. British medical journal (International ed.). 2002, Vol 325, Num 7364, pp 592-595, issn 0959-8146Article

Neue Therapieansätze beim Reizdarm = New treatments for irritable bowel syndromeMÜLLER-LISSNER, S. A; MÜLLER-LISSNER, Stefan A.Zeitschrift für Gastroenterologie. 2000, Vol 38, Num 9, pp 815-816, issn 0044-2771Article

Efficacité de l'alosetron dans les troubles fonctionnels intestinaux = Efficacity of alosetron in irritable bowel syndromeDE SAINT LOUVENT, P.Concours médical (Paris). 2000, Vol 122, Num 17-18, issn 0010-5309, p. 1158Article

Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteersCLEMENS, C. H. M; SAMSOM, M; VAN BERGE HENEGOUWEN, G. P et al.Alimentary pharmacology & therapeutics. 2002, Vol 16, Num 5, pp 993-1002, issn 0269-2813Article

Effects of 5-HT₃ antagonism on postprandial gastric volume and symptoms in humansKUO, B; CAMILLERI, M; BURTON, D et al.Alimentary pharmacology & therapeutics. 2002, Vol 16, Num 2, pp 225-233, issn 0269-2813, 9 p.Article

Serotoninergic neuroenteric modulatorsTALLEY, Nicholas J.Lancet (British edition). 2001, Vol 358, Num 9298, pp 2061-2068, issn 0140-6736Article

AlosetronThe Medical letter on drugs and therapeutics (Edition française). 2002, Vol 24, Num 18, pp 79-80, issn 0253-8512, 2 p.Article

Gender-related differences in slowing colonic transit by a 5-HT₃ antagonist in subjects with diarrhea-predominant irritable bowel syndromeVIRAMONTES, Blanca E; CAMILLERI, Michael; MCKINZIE, Sanna et al.The American journal of gastroenterology. 2001, Vol 96, Num 9, pp 2671-2676, issn 0002-9270Article

Lotronex and the FDA : a fatal erosion of integrityHORTON, Richard.Lancet (British edition). 2001, Vol 357, Num 9268, pp 1544-1545, issn 0140-6736Article

Pre-cebo: An Unrecognized Issue in the Interpretation of Adequate Relief During Irritable Bowel Syndrome Drug TrialsKIM, Sharon E; KUBOMOTO, Scott; CHUA, Kathleen et al.Journal of clinical gastroenterology. 2012, Vol 46, Num 8, pp 686-690, issn 0192-0790, 5 p.Article

Reassessing the benefits and risks of alosetron: What is its place in the treatment of irritable bowel syndrome?ANDRESEN, Viola; HOLLERBACH, Stephan.Drug safety. 2004, Vol 27, Num 5, pp 283-292, issn 0114-5916, 10 p.Article

Ischemic colitis during treatment with alosetronFRIEDEL, David; THOMAS, Rebecca; FISHER, Robert S et al.Gastroenterology (New York, NY. 1943). 2001, Vol 120, Num 2, pp 557-560, issn 0016-5085Article

Alosetron. CommentariesBALFOUR, J. A. B; GOA, K. L; PERRY, C. M et al.Drugs (Basel). 2000, Vol 59, Num 3, pp 511-520, issn 0012-6667Article

Medium term effects of a new 5HT₃ antagonist, alosetron, in patients with carcinoid diarrhoeaSASLOW, S. B; SCOLAPIO, J. S; CAMILLERI, M et al.Gut. 1998, Vol 42, Num 5, pp 628-634, issn 0017-5749Article

Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex)KOCH, Kevin; CAMPANELLA, Corinne; BAIDOO, Charlotte A et al.Digestive diseases and sciences. 2004, Vol 49, Num 7-8, pp 1244-1249, issn 0163-2116, 6 p.Article

Sex and age differences in the pharmacokinetics of alosetronKOCH, K. M; PALMER, J. L; NOORDIN, N et al.British journal of clinical pharmacology. 2002, Vol 53, Num 3, pp 238-242, issn 0306-5251Article

Serotonin receptor modulation in irritable bowel syndrome : one step forwards and one step backwardsWHORWELL, P. J.Gut. 2001, Vol 48, Num 5, pp 596-597, issn 0017-5749Article

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndromeLEMBO, Tony; WRIGHT, Richard A; BAGBY, Barbara et al.The American journal of gastroenterology. 2001, Vol 96, Num 9, pp 2662-2670, issn 0002-9270Article

Alosetron, a 5-HT₃ receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteersHOUGHTON, L. A; FOSTER, J. M; WHORWELL, P. J et al.Alimentary pharmacology & therapeutics. 2000, Vol 14, Num 6, pp 775-782, issn 0269-2813Article

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndromeOLDEN, Kevin; DEGARMO, Ronald G; JHINGRAN, Priti et al.The American journal of gastroenterology. 2002, Vol 97, Num 12, pp 3139-3146, issn 0002-9270, 8 p.Article